CN113423397A - 包含美洛昔康的药物组合物 - Google Patents

包含美洛昔康的药物组合物 Download PDF

Info

Publication number
CN113423397A
CN113423397A CN202080012487.9A CN202080012487A CN113423397A CN 113423397 A CN113423397 A CN 113423397A CN 202080012487 A CN202080012487 A CN 202080012487A CN 113423397 A CN113423397 A CN 113423397A
Authority
CN
China
Prior art keywords
meloxicam
dosage form
rizatriptan
migraine
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080012487.9A
Other languages
English (en)
Chinese (zh)
Inventor
赫里奥特·塔布提奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CN113423397A publication Critical patent/CN113423397A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
CN202080012487.9A 2019-02-06 2020-02-06 包含美洛昔康的药物组合物 Pending CN113423397A (zh)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US62/802,198 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US62/803,756 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US62/835,613 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US62/846,311 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US62/860,705 2019-06-12
US201962895956P 2019-09-04 2019-09-04
US201962895933P 2019-09-04 2019-09-04
US62/895,956 2019-09-04
US62/895,933 2019-09-04
US201962955905P 2019-12-31 2019-12-31
US62/955,905 2019-12-31
PCT/US2020/017046 WO2020163620A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du méloxicam

Publications (1)

Publication Number Publication Date
CN113423397A true CN113423397A (zh) 2021-09-21

Family

ID=71947112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080012487.9A Pending CN113423397A (zh) 2019-02-06 2020-02-06 包含美洛昔康的药物组合物

Country Status (17)

Country Link
EP (1) EP3920909A4 (fr)
JP (3) JP7237386B2 (fr)
KR (1) KR20210118880A (fr)
CN (1) CN113423397A (fr)
AU (2) AU2020218253B2 (fr)
BR (1) BR112021015467A2 (fr)
CA (2) CA3213549A1 (fr)
CL (1) CL2021002070A1 (fr)
CO (1) CO2021010380A2 (fr)
CR (1) CR20210420A (fr)
EC (1) ECSP21060962A (fr)
IL (1) IL285389A (fr)
MA (1) MA54904A (fr)
MX (1) MX2021009435A (fr)
PE (1) PE20212157A1 (fr)
SG (1) SG11202107926XA (fr)
WO (1) WO2020163620A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021414212A1 (en) * 2020-12-31 2023-07-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2016131067A2 (fr) * 2015-02-10 2016-08-18 Antecip Bioventures Ii Llc Compositions pharmaceutiques contenant du méloxicam
US20180280306A1 (en) * 2017-01-04 2018-10-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348979A1 (fr) * 1998-11-02 2000-05-11 Merck & Co., Inc. Methode de traitement des migraines et compositions pharmaceutiques associees
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
PT3100728T (pt) * 2009-05-13 2020-02-21 Cydex Pharmaceuticals Inc Composições farmacêuticas que compreendem prasugrel e derivados da ciclodextrina e métodos de produção e utilização dos mesmos
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3256138T3 (da) * 2015-11-25 2022-05-16 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam
SG10201913032TA (en) * 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine
KR102627411B1 (ko) * 2017-01-04 2024-01-18 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
CA3063095A1 (fr) * 2017-05-10 2018-11-15 Axsome Therapeutics, Inc. Compositions pharmaceutiques comportant un anti-inflammatoire non steroidien

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2016131067A2 (fr) * 2015-02-10 2016-08-18 Antecip Bioventures Ii Llc Compositions pharmaceutiques contenant du méloxicam
US20180280306A1 (en) * 2017-01-04 2018-10-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Also Published As

Publication number Publication date
AU2020218253A1 (en) 2021-08-12
KR20210118880A (ko) 2021-10-01
MA54904A (fr) 2021-12-15
CL2021002070A1 (es) 2022-04-01
EP3920909A4 (fr) 2022-11-30
JP7420990B2 (ja) 2024-01-23
MX2021009435A (es) 2021-09-10
JP7237386B2 (ja) 2023-03-13
JP2023062144A (ja) 2023-05-02
CR20210420A (es) 2021-12-22
CA3128940C (fr) 2023-11-07
WO2020163620A1 (fr) 2020-08-13
JP2024026732A (ja) 2024-02-28
CO2021010380A2 (es) 2021-09-30
AU2023202545A1 (en) 2023-05-18
IL285389A (en) 2021-09-30
EP3920909A1 (fr) 2021-12-15
AU2020218253B2 (en) 2023-02-23
SG11202107926XA (en) 2021-08-30
CA3128940A1 (fr) 2020-08-13
BR112021015467A2 (pt) 2021-10-05
PE20212157A1 (es) 2021-11-09
JP2022519670A (ja) 2022-03-24
CA3213549A1 (fr) 2020-08-13
ECSP21060962A (es) 2021-11-30

Similar Documents

Publication Publication Date Title
US11285213B2 (en) Pharmaceutical compositions comprising meloxicam
US11426414B2 (en) Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) Pharmaceutical compositions comprising meloxicam
US20200246462A1 (en) Pharmaceutical compositions comprising meloxicam
US20200376125A1 (en) Pharmaceutical compositions comprising meloxicam
US20210369845A1 (en) Pharmaceutical compositions comprising meloxicam
US20210177971A1 (en) Pharmaceutical compositions comprising meloxicam
US20200179396A1 (en) Pharmaceutical compositions comprising meloxicam
CN112384198A (zh) 包含美洛昔康的药物组合物
US11865117B2 (en) Pharmaceutical compositions comprising meloxicam
CN115697326A (zh) 包含美洛昔康的药物组合物
CN116887838A (zh) 包含美洛昔康的药物组合物
JP2024026732A (ja) メロキシカムおよびリザトリプタンを含有する組み合わせの使用
US20240197887A1 (en) Pharmaceutical compositions comprising meloxicam

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060654

Country of ref document: HK